Cargando…
Staphylococcal alpha-toxin tilts the balance between malignant and non-malignant CD4(+) T cells in cutaneous T-cell lymphoma
Staphylococcus aureus is implicated in disease progression in cutaneous T-cell lymphoma (CTCL). Here, we demonstrate that malignant T cell lines derived from CTCL patients as well as primary malignant CD4(+) T cells from Sézary syndrome patients are considerably more resistant to alpha-toxin-induced...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791457/ https://www.ncbi.nlm.nih.gov/pubmed/31646088 http://dx.doi.org/10.1080/2162402X.2019.1641387 |
Sumario: | Staphylococcus aureus is implicated in disease progression in cutaneous T-cell lymphoma (CTCL). Here, we demonstrate that malignant T cell lines derived from CTCL patients as well as primary malignant CD4(+) T cells from Sézary syndrome patients are considerably more resistant to alpha-toxin-induced cell death than their non-malignant counterparts. Thus, in a subset of Sézary syndrome patients the ratio between malignant and non-malignant CD4(+) T cells increases significantly following exposure to alpha-toxin. Whereas toxin-induced cell death is ADAM10 dependent in healthy CD4(+) T cells, resistance to alpha-toxin in malignant T cells involves both downregulation of ADAM10 as well as other resistance mechanisms. In conclusion, we provide first evidence that Staphylococcus aureus derived alpha-toxin can tilt the balance between malignant and non-malignant CD4(+) T cells in CTCL patients. Consequently, alpha-toxin may promote disease progression through positive selection of malignant CD4(+) T cells, identifying alpha-toxin as a putative drug target in CTCL. |
---|